Based on the trial results, zenocutuzumab obtained FDA approval for adults with advanced, unresectable, or metastatic NSCLC and PDAC harboring NRG1 gene fusion with disease progression during or after prior systemic therapy [99]. The gene discussed is NRG1; the disease is non-small cell lung carcinoma.